Unity Biotechnology
Unity Biotechnology is a startup biotechnology company that develops drugs which target senescent cells. The company's products in development include UBX1325 that targets Bcl-xL, a mechanism to eliminate senescent cells in age-related eye diseases (in Phase 1 clinical trials for diabetic macular edema as of October 2020), UBX0101, targeting knee osteoarthritis (in Phase I clinical trials as of June 2018), and UBX1967, a preclinical product targeting ophthalmologic diseases. All are senolytic medicines.
Link from a Wikipage to another Wikipage
primaryTopic
Unity Biotechnology
Unity Biotechnology is a startup biotechnology company that develops drugs which target senescent cells. The company's products in development include UBX1325 that targets Bcl-xL, a mechanism to eliminate senescent cells in age-related eye diseases (in Phase 1 clinical trials for diabetic macular edema as of October 2020), UBX0101, targeting knee osteoarthritis (in Phase I clinical trials as of June 2018), and UBX1967, a preclinical product targeting ophthalmologic diseases. All are senolytic medicines.
has abstract
Unity Biotechnology is a start ...... severe painful osteoarthritis.
@en
country
founded by
founding year
industry
location city
państwo
number of employees
type
Link from a Wikipage to an external page
Wikipage page ID
56,881,445
page length (characters) of wiki page
Wikipage revision ID
1,019,217,850
Link from a Wikipage to another Wikipage
founded
in California, United States of America
@en
founders
Judith Campisi, Jan van Deursen, Nathaniel “Ned” David, Daohong Zhou
@en
hq location city
hq location country
industry
logo
@en
name
Unity Biotechnology
@en
num employees
num employees year
predecessor
Forge, Inc.
@en
traded as
NASDAQ:UBX
@en
Russell 2000 Index component
@en
type
wikiPageUsesTemplate
subject
comment
Unity Biotechnology is a start ...... . All are senolytic medicines.
@en
label
Unity Biotechnology
@en
sameAs
wasDerivedFrom
homepage
isPrimaryTopicOf
name
Unity Biotechnology
@en